[Delayed-release verapamil hydrochloride in chronic atrial fibrillation. Reducing the heart rate].
In an open clinical trial, the therapeutic effect of sustained-release verapamil hydrochloride was investigated in 40 patients with chronic atrial fibrillation. As required, the daily dose was increased from 240 mg to 480 mg. A clinically relevant, statistically significant decrease in the heart rate was observed in almost all the patients. Since only four patients experienced mild side effects, with no major clinical significance, the preparation has a positive benefit/risk ratio for the indication investigated.
Gonska
B D
BD
Medizinische Klinik, Abteilung Kardiologie, Universität Göttingen.
Wiedey
K D
KD
D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D014700:Verapamil / Q000008:administration & dosage / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D014700:Verapamil
Retardiertes Verapamilhydrochlorid bei chronischem Vorhofflimmern. Senkung der Herzfrequenz.